The Phase 3 programme , understood to be known as the TRIUMPH trials, is now underway and is evaluating retatrutide across broader and more diverse patient populations, including individuals with: Obesity without type 2 diabetes Obesity with type 2 diabetes Obesity-related cardiovascular disease Metabolic dysfunction-associated steatohepatitis (MASH) Readers seeking the most current information on trial status, registered populations, and endpoints are encouraged to consult ClinicalTrials.gov directly, where Phase 3 trial registrations for retatrutide can be found
Nutrition and lifestyle guidance
It targets three hormones at the same time: GLP-1, GIP, and glucagon
Seamless switching process with full 24/7 support
Side effects that persist or worsen may indicate that a different medication or a different approach is more appropriate
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have garnered recognition as potentially revolutionary therapeutic modalities for MASLD/MASH management, offering multifaceted benefits extending beyond glycemic regulation
